Objective: To investigate the clinical efficacy of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of gastrointestinal tumors with angina pectoris. Methods: We enrolled the 58 patients with digestive tract tumor merger angina in November 2017 - October 2019 and analysis the hospital clinical data by retrospective method. We included patients with routine treatment in control group (n = 31 cases) and the subjects treated with increased dose of succinic acid metoprololzyban joint with trimetazidineinobservation group (n = 27 cases) according to the different treatment group. Results: The effective rate of angina pectoris treatment in the observation group was higher than that in the control group. Furthermore, the incidence of adverse reactions was lower than that in the control group and the difference was statistically significant (P < 0.05). Conclusion: Metoprolol succinic acid sustained release tablets combined with trimetazidine in the treatment of gastrointestinal tumors with angina pectoris can improve the efficacy of angina pectoris. The drug use is safe and worthy of clinical use.